Flightpath Biosciences, founded with a mission to revolutionize drug discovery and delivery, focuses on developing advanced therapeutic candidates and cutting-edge drug delivery technologies. The company aims to enhance drug targeting and safety, minimize negative impacts on the microbiome, accelerate time-to-market, and eliminate non-target antibiotic resistance. Their market focus is on pathogen-driven diseases, offering first-in-class, selective antibiotic therapies.

Notable affiliated individuals include leading scientists in the field of microbiology and pharmacology. The company has garnered significant attention from prominent investors and partners in the biotech industry. Key achievements include initiating human clinical testing of the world's first narrow-spectrum antibiotic targeting specific pathogens. Flightpath Biosciences has made a substantial impact by advancing therapies that promise to improve patient outcomes while addressing critical issues like antibiotic resistance.